BPC-157: What the Research Actually Shows About This Healing Peptide

What Is BPC-157?

BPC-157 is a synthetic 15-amino acid peptide derived from a protein found in human gastric juice. It has been extensively studied in animal models for tissue repair, but no human clinical trials have been published to date.

BPC-157 (Body Protection Compound-157) is a synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was first characterized by researchers at the University of Zagreb in the early 1990s and has since become one of the most discussed peptides in research communities focused on injury recovery.

The parent protein (simply called BPC) is found in human gastric juice at nanogram concentrations and appears to play a role in protecting and repairing the gastrointestinal lining. BPC-157 is a stable fragment of this larger protein, selected for its relative resistance to degradation.

Unlike growth hormone secretagogues such as CJC-1295 or ipamorelin, BPC-157 does not operate through growth hormone-releasing pathways. Its studied mechanisms center on angiogenesis, nitric oxide signaling, and growth factor modulation, placing it in a different category entirely from the GH-related peptides.

Who this page is for, and who it isn’t for

This page is for people who want to understand what BPC-157 research has actually demonstrated, where the evidence stands, and what remains unknown. It is written for researchers, clinicians, and informed readers evaluating the preclinical literature.

This page is not a treatment guide, a buying recommendation, or medical advice. If you are dealing with an injury, consult a qualified healthcare provider. BPC-157 has not been approved for human use by any regulatory agency.

How BPC-157 Is Thought to Work

The proposed mechanisms come primarily from animal studies and cell culture experiments. While the preclinical findings are consistent across many models, their applicability to humans has not been confirmed.

Angiogenesis (new blood vessel formation)

BPC-157 has been observed to upregulate vascular endothelial growth factor (VEGF) expression in animal tissue, promoting the formation of new blood vessels at injury sites. This was demonstrated in chicken embryo models (chorioallantoic membrane assay) and in rat models of ischemic injury (Sikiric et al., 2018).

New vasculature is important for healing because it delivers oxygen, nutrients, and immune cells to damaged tissue. The degree to which exogenous BPC-157 meaningfully enhances this process beyond the body’s innate response has not been established in humans.

Nitric oxide system modulation

BPC-157 appears to interact with the nitric oxide (NO) system in a bidirectional manner, counteracting both excessive NO and NO-synthase inhibition in animal models. This stabilizing effect is potentially significant because NO is involved in vasodilation, inflammation regulation, and tissue repair signaling (Sikiric et al., 2014).

Growth factor upregulation

In preclinical experiments, BPC-157 has been associated with increased expression of several growth factors:

• EGF (epidermal growth factor) and its receptor
• NGF (nerve growth factor)
• VEGF (vascular endothelial growth factor)
• FAK-paxillin pathway activation, which is involved in cell migration during wound healing

Collagen and tendon fibroblast effects

In vitro, BPC-157 promoted fibroblast outgrowth and increased type I collagen expression, directly relevant to tendon and ligament repair. Tendon fibroblast migration and proliferation increased in a dose-dependent manner (Chang et al., 2011).

Gastrointestinal protective effects

As a compound derived from gastric juice proteins, BPC-157 has shown gastroprotective effects in multiple animal models. It has been studied against lesions induced by NSAIDs, alcohol, and various cytotoxic agents. The proposed mechanisms involve cytoprotection, maintenance of mucosal integrity, and modulation of the prostaglandin system (Sikiric et al., 2011).

What the Preclinical Research Shows

All of the studies summarized below were conducted in animals (primarily rats) or cell cultures. This is a critical limitation. Preclinical results frequently do not translate to humans.

Tendon and muscle healing

In a rat Achilles tendon transection model, BPC-157 administered intraperitoneally improved biomechanical properties of healing tendons compared to controls, including increased tensile strength and collagen organization (Staresinic et al., 2003).

A separate study in rats with quadriceps crush injuries found that BPC-157 at 10 μg/kg (intraperitoneal) accelerated functional recovery and histological healing. The peptide appeared to promote organized muscle fiber regeneration rather than disorganized scar tissue (Pevec et al., 2010).

These findings are consistent across several research groups, which strengthens the preclinical case. However, no controlled human study has replicated these results.

Gut healing

BPC-157 has been studied across numerous GI models in animals:

• Inflammatory bowel disease models: reduced mucosal damage and inflammation in both acute and chronic colitis in rats
• NSAID-induced damage: counteracted gastric and intestinal lesions caused by diclofenac, aspirin, and other NSAIDs
• Esophageal damage: accelerated healing of esophagitis in rat models
• Fistula healing: promoted closure of GI fistulas in animal models

(Sikiric et al., 2016)

The GI research is arguably the most consistent body of evidence for BPC-157, which is unsurprising given the peptide’s origin in gastric juice.

Nerve repair

In rat models of peripheral nerve transection, BPC-157 promoted nerve regeneration and functional recovery. The peptide enhanced both proximal and distal nerve stump outgrowth and improved electrophysiological parameters of regenerating nerves (Gjurasin et al., 2010).

Bone healing

BPC-157 at 10 μg/kg/day was studied in a rat segmental bone defect model and appeared to accelerate fracture healing, with improved bone density, callus formation, and biomechanical strength at 2 and 4 weeks (Krivic et al., 2006).

The critical gap: no published human trials

Despite the breadth of animal research, no peer-reviewed human clinical trial for BPC-157 has been published. A Phase I trial (under the name “PL 14736” or “PL-10”) for inflammatory bowel disease was reportedly conducted, but results never appeared in a peer-reviewed journal. The absence of published human data after three decades of animal research is notable and should inform how this peptide’s potential is evaluated.

What BPC-157 Has Been Studied For (Summary)

Based on the available preclinical literature, BPC-157 has been investigated for:

• Tendon and ligament healing: consistent findings across multiple injury models
• Muscle injury recovery: observed faster return to function in crush injury models
• Gut protection and healing: the most extensive evidence base, spanning multiple GI damage models
• Nerve regeneration: improved functional recovery after peripheral nerve injuries in rats
• Bone fracture healing: accelerated union in rat models
• Anti-inflammatory activity: modulation of inflammatory cytokines
• Counteraction of NSAID-induced GI damage: a distinctive and well-documented finding
• Wound healing: faster skin wound closure with improved tissue organization

None of these applications have been confirmed in human clinical trials.

Community-Reported Protocols

The following information reflects protocols commonly discussed in research communities and online forums. No human clinical trial has established dosing for BPC-157. This section is included for informational completeness and is not medical advice or a recommendation.

Subcutaneous injection (most commonly reported)

• Typical reported dose: 250–500 mcg per day
• Reported range: 200–800 mcg per day
• Frequency: once or twice daily
• Injection site: subcutaneously, often near the area of concern
• Reported cycle length: 4–8 weeks

Oral administration

• Typical reported dose: 250–500 mcg per day
• Primarily discussed for GI-related applications
• BPC-157 is reported to be unusually stable in gastric acid compared to most peptides, and animal studies have used both oral and injectable routes

Basis for these numbers

Most rat studies use 10 μg/kg body weight (intraperitoneal or oral). Standard allometric scaling to an 80 kg human yields approximately 600–800 mcg, though allometric scaling from rats to humans is inherently imprecise. Community doses of 250–500 mcg may reflect practical and economic factors as much as pharmacological reasoning.

Reconstitution

BPC-157 is typically supplied as a lyophilized powder. Common reconstitution: 5 mg vial with 2 mL bacteriostatic water yields 2,500 mcg/mL. Reconstituted solutions are typically stored refrigerated (2–8°C) and used within 3–4 weeks. For detailed handling steps, see the storage and reconstitution guide.

Oral vs. Injectable BPC-157: What the Evidence Distinguishes

A frequently debated topic in BPC-157 discussions is whether the peptide should be administered orally or by injection. The answer depends on the intended target tissue, and the distinction is worth understanding.

BPC-157 is unusual among peptides in that it has been studied via both oral and injectable routes in animal models. Its gastric origin (it is a fragment of a protein found in gastric juice) appears to confer unusual stability in acidic conditions — most peptides would be destroyed in the stomach, but BPC-157 has demonstrated biological activity in animal studies when administered orally.

Oral administration has been studied primarily for gastrointestinal applications: gut mucosal healing, NSAID-induced damage, inflammatory bowel models, and esophageal repair. The rationale is direct: an orally administered peptide contacts the GI lining directly, where local concentrations may be therapeutically relevant even if systemic bioavailability is low.

Injectable administration (intraperitoneal in most animal studies, subcutaneous in community protocols) has been studied for systemic applications: tendon, ligament, muscle, bone, and nerve repair. These tissues require the peptide to reach the injury site through the bloodstream.

The critical question — does oral BPC-157 achieve meaningful systemic levels? — has not been definitively answered in published research. Some animal studies show systemic effects from oral dosing (e.g., tendon healing in rats given BPC-157 in drinking water), but whether the active compound reaches systemic circulation intact or whether the effect is mediated through gut-systemic signaling pathways (such as the gut-brain axis or vagus nerve) remains unclear.

This distinction is practically important: if someone is interested in BPC-157 for gut-related issues, the oral route has a plausible mechanism. For musculoskeletal injuries distant from the GI tract, the injectable route has stronger mechanistic support in the preclinical literature. Neither route has been validated in human clinical trials.

For more on why administration routes matter across peptides, see how peptides are administered.

Side Effects and Safety Considerations

Limited human safety data exists. The following reflects community-reported experiences and theoretical concerns.

Commonly reported side effects

BPC-157 is generally described as well-tolerated in community reports. The most frequently mentioned effects are mild:

• Injection site reactions: redness, mild pain, bruising (common with any subcutaneous injection)
• Nausea: occasionally reported, typically transient
• Dizziness: rare, usually mild
• Headache: infrequently reported

Theoretical concerns

Angiogenesis and cancer risk: Because BPC-157 promotes blood vessel formation in preclinical models, there is a theoretical concern about use in individuals with active or undiagnosed cancers. Tumors depend on angiogenesis to grow, and any pro-angiogenic compound could theoretically support tumor growth. One study found BPC-157 did not promote tumor growth in a melanoma model (Sikiric et al., 2018), but this question has not been adequately studied.

Growth factor modulation: The upregulation of multiple growth factors raises questions about long-term effects that have not been investigated.

Unknown long-term effects: Reproductive toxicity, carcinogenicity, and drug interaction studies have not been conducted. The absence of this data does not mean BPC-157 is dangerous. It means we do not know.

How BPC-157 Relates to Other Peptides

BPC-157 is frequently discussed alongside other peptides studied for healing and recovery:

• TB-500 (thymosin beta-4): a different healing peptide that operates through actin regulation and systemic cell signaling. The two are often discussed together as complementary approaches, with TB-500 described as more systemic and BPC-157 as more localized. See our injury recovery guide for a comparison.
• GHK-Cu: a copper peptide studied for collagen remodeling and anti-aging applications, operating through different pathways than BPC-157.
• Growth hormone secretagogues like ipamorelin or CJC-1295: sometimes discussed alongside BPC-157 for recovery contexts, since elevated GH/IGF-1 supports an anabolic environment. These operate through entirely different receptor systems.
• LL-37: an antimicrobial peptide also studied for wound healing, with some overlapping research interest.

Legal Status

United States

BPC-157 is not FDA-approved for any human use. It is not a controlled substance. It has been sold as a “research chemical,” legally purchasable for in vitro research purposes but not marketed for human consumption. The FDA issued warning letters to some compounding pharmacies in 2023–2024 regarding BPC-157 products.

Australia

Listed as a Schedule 4 (prescription-only) substance by the TGA as of 2023.

European Union

Regulatory status varies by country. Generally available as a research chemical but not approved for clinical use.

WADA status

BPC-157 is not currently explicitly listed on the WADA Prohibited List, but athletes should note that peptide regulations evolve and some anti-doping authorities may classify it under broader provisions for peptide hormones.

Frequently Asked Questions

Does BPC-157 have any published human clinical trials?

No. As of early 2026, no peer-reviewed human clinical trial data for BPC-157 has been published. All evidence comes from animal studies (primarily in rats) and in vitro (cell culture) experiments. While the preclinical data is extensive, the absence of human data is a significant limitation.

Is BPC-157 safe?

The honest answer is that we do not have enough data to make definitive safety claims. Community reports generally describe it as well-tolerated, and the animal literature has not identified major toxicity signals. However, long-term human safety has not been studied. No human pharmacokinetic or toxicology studies have been published.

Can BPC-157 be taken orally?

Animal studies have demonstrated efficacy through both oral and injectable routes, and BPC-157 shows unusual stability in gastric acid compared to most peptides. Oral administration is primarily discussed for GI-related applications. The relative bioavailability of oral versus injectable BPC-157 in humans has not been formally studied.

How does BPC-157 compare to TB-500?

BPC-157 and TB-500 operate through different mechanisms. BPC-157’s studied effects center on angiogenesis, NO modulation, and growth factor upregulation, with effects often described as more localized. TB-500 (thymosin beta-4) works primarily through actin regulation and is studied as a more systemic healing peptide. They are frequently discussed together for injury recovery. See our injury recovery peptide guide for more detail.

Does BPC-157 show up on drug tests?

Standard workplace drug panels do not test for BPC-157. Specialized peptide testing (such as protocols used in professional sports anti-doping programs) could potentially detect it.

Should BPC-157 be injected near the injury site?

Community protocols generally describe subcutaneous injection near the area of interest. Animal research has used both local and systemic (intraperitoneal) administration with reported positive results, suggesting both approaches may have merit. No human comparative study exists to determine whether local injection confers meaningful advantages over systemic administration.

References

1. Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol. 2016;14(8):857-865. PubMed
2. Sikiric P, et al. “Stable Gastric Pentadecapeptide BPC 157-NO-system Relation.” Curr Pharm Des. 2014;20(7):1126-35. PubMed
3. Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol. 2011;110(3):774-80. PubMed
4. Staresinic M, et al. “Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.” J Orthop Res. 2003;21(6):976-83. PubMed
5. Pevec D, et al. “Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application.” Med Sci Monit. 2010;16(3):BR81-88. PubMed
6. Sikiric P, et al. “Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems.” Curr Pharm Des. 2018;24(18):1946-1956. PubMed
7. Gjurasin M, et al. “Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions.” Life Sci. 2010;82(3-4):116-22. PubMed
8. Krivic A, et al. “Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and target reversal.” J Orthop Res. 2006;24(5):982-9. PubMed
9. Sikiric P, et al. “Pentadecapeptide BPC 157 and the gastrointestinal tract.” Curr Med Chem. 2011;18(29):4547-56. PubMed

Related Articles

Peptide

GHK-Cu (Copper Peptide): Research, Mechanism, and Evidence for Tissue Repair

An evidence-based review of GHK-Cu — the naturally occurring copper tripeptide studied for wound healing, skin aging, and gene expression modulation. What the research shows.

Peptide

LL-37: What the Research Shows About This Human Antimicrobial Peptide

An evidence-based review of LL-37 (cathelicidin) — research on antimicrobial activity, immune modulation, wound healing, and safety considerations.

Peptide

TB-500 (Thymosin Beta-4): What the Research Shows About This Healing Peptide

An evidence-first review of TB-500 and thymosin beta-4 — preclinical findings on systemic healing, inflammation, and tissue repair, with an honest look at the state of the evidence.